Wayne Gretzky has a face-off with his younger self in new GSK ad
WEBOct 30, 2023 · “The Arexvy ad featuring Wayne Gretzky aims to dispel the misperception that RSV is only a concern for young children and encourages adults aged 60 and older, who are among those at greater...
AREXVY TV Commercials - iSpot.tv
WEBChoose A Better Way To Measure TV ROAS. Watch, interact and learn more about the songs, characters, and celebrities that appear in your favorite AREXVY TV Commercials. Watch the commercial, share it with friends, then discover more great AREXVY TV commercials on iSpot.tv.
AREXVY TV Spot, 'RSV Protection' - iSpot.tv
WEBJan 1, 2024 · Check out AREXVY's 60 second TV commercial, 'RSV Protection' from the Rx: Allergies, Cold & Flu industry. Keep an eye on this page to learn about the songs, characters, and celebrities appearing in this TV commercial.
New RSV vaccines can be powerful tools, but rollout poses test
WEBSep 18, 2023 · Beginning this spring, GSK has run ads featuring former professional basketball player Earvin “Magic” Johnson to raise RSV awareness. Pfizer, in its own campaign, warns older adults that RSV is “not just a cold.” Meanwhile, Sanofi has taken to social media to explain the risks of RSV to infants.
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Arexvy is the first RSV vaccine approved by the FDA for the prevention of lower respiratory tract disease in individuals 60 years of age and older. The vaccine reduced the risk of RSV-associated...
US FDA approves expanded age indication for GSK’s Arexvy, the …
WEBJun 7, 2024 · GSK announced that the US FDA has expanded the age indication for its RSV vaccine, Arexvy, to include adults aged 50-59 who are at increased risk of severe RSV outcomes. The vaccine is also approved for adults 60 …
US FDA approves GSK’s Arexvy, the world’s first respiratory …
WEBMay 3, 2023 · Arexvy is a recombinant subunit vaccine with adjuvant that prevents lower respiratory tract disease caused by RSV in adults aged 60 and older. It showed 82.6% efficacy in the pivotal trial and will be available before the 2023/24 RSV season in the US.
GSK announces AREXVY, its respiratory syncytial virus (RSV) …
WEBAug 17, 2023 · AREXVY is the first FDA-approved RSV vaccine for adults 60 and older, indicated for the prevention of lower respiratory tract disease caused by RSV. It is now available at all major retail pharmacies and may be covered by most insurance plans.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · AREXVY is the first RSV vaccine approved by the US FDA for adults aged 60 and older. It is a recombinant subunit vaccine with an adjuvant that showed high efficacy against RSV-LRTD and severe RSV-LRTD in clinical trials.
FAQs | AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)
WEBAREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in people 60 years of age and older. Learn about the vaccine, its effectiveness, side effects, coverage, and availability.
- Some results have been removed